|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2006-12-5
|
|
pubmed:abstractText |
Standard treatments have modest effect against pancreatic cancer, and current research focuses on agents targeting molecular pathways involved in tumor growth and angiogenesis. This study investigated the interactions between ZD6474, an inhibitor of tyrosine kinase activities of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor (EGFR), gemcitabine, and ionizing radiation in human pancreatic cancer cells and analyzed the molecular mechanisms underlying this combination.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BiancoCataldoC,
pubmed-author:CiardielloFortunatoF,
pubmed-author:CioniniLucaL,
pubmed-author:DanesiRomanoR,
pubmed-author:Del TaccaMarioM,
pubmed-author:EckhardtGailG,
pubmed-author:GiovannettiElisaE,
pubmed-author:MeyValentinaV,
pubmed-author:NannizziSaraS,
pubmed-author:PasqualettiFrancescoF,
pubmed-author:RabenDavidD,
pubmed-author:RicciardiSimonaS,
pubmed-author:TortoraGiampaoloG,
pubmed-author:TroianiTeresaT,
pubmed-author:de LiguoroMarioM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7099-107
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17145834-Animals,
pubmed-meshheading:17145834-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17145834-Apoptosis,
pubmed-meshheading:17145834-Cell Cycle,
pubmed-meshheading:17145834-Cell Line, Tumor,
pubmed-meshheading:17145834-Cell Proliferation,
pubmed-meshheading:17145834-Combined Modality Therapy,
pubmed-meshheading:17145834-Deoxycytidine,
pubmed-meshheading:17145834-Deoxycytidine Kinase,
pubmed-meshheading:17145834-Disease Models, Animal,
pubmed-meshheading:17145834-Dose-Response Relationship, Radiation,
pubmed-meshheading:17145834-Drug Screening Assays, Antitumor,
pubmed-meshheading:17145834-Drug Synergism,
pubmed-meshheading:17145834-Female,
pubmed-meshheading:17145834-Gene Expression Profiling,
pubmed-meshheading:17145834-Humans,
pubmed-meshheading:17145834-Mice,
pubmed-meshheading:17145834-Mice, Nude,
pubmed-meshheading:17145834-Pancreatic Neoplasms,
pubmed-meshheading:17145834-Phosphorylation,
pubmed-meshheading:17145834-Piperidines,
pubmed-meshheading:17145834-Polymerase Chain Reaction,
pubmed-meshheading:17145834-Predictive Value of Tests,
pubmed-meshheading:17145834-Quinazolines,
pubmed-meshheading:17145834-Radiation, Ionizing,
pubmed-meshheading:17145834-Receptor, Epidermal Growth Factor,
pubmed-meshheading:17145834-Receptors, Vascular Endothelial Growth Factor,
pubmed-meshheading:17145834-Signal Transduction,
pubmed-meshheading:17145834-Transplantation, Heterologous
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
|
|
pubmed:affiliation |
Division of Radiotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy.
|
|
pubmed:publicationType |
Journal Article
|
